OncoSec Medical Stock Forecast, Price & News

OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

Is OncoSec Medical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OncoSec Medical stock.
View analyst ratings for OncoSec Medical or view top-rated stocks.

What stocks does MarketBeat like better than OncoSec Medical?

Wall Street analysts have given OncoSec Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OncoSec Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OncoSec Medical?

OncoSec Medical saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 1,150,000 shares, an increase of 20.3% from the July 29th total of 955,900 shares. Based on an average trading volume of 1,660,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 6.8% of the shares of the company are short sold.
View OncoSec Medical's Short Interest.

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for OncoSec Medical.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) released its quarterly earnings data on Sunday, March, 14th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.01.
View OncoSec Medical's earnings history.

How has OncoSec Medical's stock been impacted by COVID-19 (Coronavirus)?

OncoSec Medical's stock was trading at $1.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ONCS stock has increased by 65.0% and is now trading at $2.26.
View which stocks have been most impacted by COVID-19.

When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work?

OncoSec Medical's stock reverse split on the morning of Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ONCS?

3 Wall Street analysts have issued 1 year price targets for OncoSec Medical's shares. Their forecasts range from $10.00 to $12.00. On average, they expect OncoSec Medical's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 386.7% from the stock's current price.
View analysts' price targets for OncoSec Medical or view top-rated stocks among Wall Street analysts.

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the following people:

• Robert J. DelAversano, Vice President-Finance & Controller
• Christopher G. Twitty, Chief Scientific Officer
• Sandra Aung, Chief Clinical Development Officer & Senior VP
• Keir Loiacono, Chief Compliance Officer & Vice President-Legal
• Robert W. Ashworth, Senior Vice President-Regulatory Quality & CMC

What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical CEO Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among OncoSec Medical's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of OncoSec Medical's key competitors?

Some companies that are related to OncoSec Medical include Enochian Biosciences (ENOB), Vera Therapeutics (VERA), Athenex (ATNX), Sensei Biotherapeutics (SNSE), Khosla Ventures Acquisition (KVSA), Capstar Special Purpose Acquisition (CPSR), Cogent Biosciences (COGT), CytomX Therapeutics (CTMX), 9 Meters Biopharma (NMTR), ESSA Pharma (EPIX), Immutep (IMMP), MEI Pharma (MEIP), Immunome (IMNM), Esperion Therapeutics (ESPR) and Matinas BioPharma (MTNB).
View all of ONCS's competitors.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), The Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

Who are OncoSec Medical's major shareholders?

OncoSec Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.76%), Renaissance Technologies LLC (1.00%), Geode Capital Management LLC (0.47%), Caxton Corp (0.41%), Salzhauer Michael (0.12%) and Boothbay Fund Management LLC (0.12%). Company insiders that own OncoSec Medical stock include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, Grand Pharmaceutical & H China, Robert J Delaversano, Sara Bonstein and Yuhang Zhao.
View institutional ownership trends for OncoSec Medical.

Which major investors are selling OncoSec Medical stock?

ONCS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Millennium Management LLC, Citadel Advisors LLC, and Schonfeld Strategic Advisors LLC. Company insiders that have sold OncoSec Medical company stock in the last year include Alpha Holdings, Inc, Brian A Leuthner, Daniel J O'connor, and Robert J Delaversano.
View insider buying and selling activity for OncoSec Medical or view top insider-selling stocks.

Which major investors are buying OncoSec Medical stock?

ONCS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Boothbay Fund Management LLC, Caxton Corp, Geode Capital Management LLC, GSA Capital Partners LLP, Shay Capital LLC, State Street Corp, and Envestnet Asset Management Inc.. Company insiders that have bought OncoSec Medical stock in the last two years include Grand Pharmaceutical & H China, and Yuhang Zhao.
View insider buying and selling activity for OncoSec Medical or or view top insider-buying stocks.

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $2.26.

How much money does OncoSec Medical make?

OncoSec Medical has a market capitalization of $88.56 million. The biotechnology company earns $-42,250,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does OncoSec Medical have?

OncoSec Medical employs 44 workers across the globe.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is www.oncosec.com.

Where are OncoSec Medical's headquarters?

OncoSec Medical is headquartered at 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 662-6732 or via email at [email protected].